Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
38
CLVLY Quote, Financials, Valuation and Earnings
Last price:
$8.15
Seasonality move
:
1.87%
Day range:
$8.05 - $8.15
52-week range:
$6.00 - $9.00
Dividend yield:
0.4%
P/E ratio:
17.59x
P/S ratio:
6.70x
P/B ratio:
2.88x
Volume:
1.4K
Avg. volume:
2.3K
1-year change:
-3.72%
Market cap:
$408.9M
Revenue:
$61.5M
EPS (TTM):
$0.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CLVLY
Clinuvel Pharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $16.49 |
|
MESO
Mesoblast Ltd.
|
$20.3M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CLVLY
Clinuvel Pharmaceuticals Ltd.
|
$8.15 | -- | $408.9M | 17.59x | $0.03 | 0.4% | 6.70x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.42 | $12.00 | $62M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$1.80 | $9.50 | $262M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
$15.05 | $16.49 | $25.1M | -- | $0.00 | 0% | 680.02x |
|
MESO
Mesoblast Ltd.
|
$17.87 | $35.00 | $2.3B | -- | $0.00 | 0% | 125.41x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CLVLY
Clinuvel Pharmaceuticals Ltd.
|
0.33% | 0.434 | -- | 16.37x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -1.575 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.640 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 5.445 | 5.57% | 0.07x |
|
MESO
Mesoblast Ltd.
|
-- | 0.345 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CLVLY
Clinuvel Pharmaceuticals Ltd.
|
-- | -- | 19.39% | 19.45% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Clinuvel Pharmaceuticals Ltd. vs. Competitors
-
Which has Higher Returns CLVLY or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Clinuvel Pharmaceuticals Ltd.'s net margin of --. Clinuvel Pharmaceuticals Ltd.'s return on equity of 19.45% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLVLYClinuvel Pharmaceuticals Ltd.-- -- $135.6M ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About CLVLY or ATHE?
Clinuvel Pharmaceuticals Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 250.88%. Given that Alterity Therapeutics Ltd. has higher upside potential than Clinuvel Pharmaceuticals Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Clinuvel Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CLVLYClinuvel Pharmaceuticals Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is CLVLY or ATHE More Risky?
Clinuvel Pharmaceuticals Ltd. has a beta of 1.130, which suggesting that the stock is 13.043% more volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.023, suggesting its less volatile than the S&P 500 by 97.656%.
-
Which is a Better Dividend Stock CLVLY or ATHE?
Clinuvel Pharmaceuticals Ltd. has a quarterly dividend of $0.03 per share corresponding to a yield of 0.4%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clinuvel Pharmaceuticals Ltd. pays 5.58% of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend. Clinuvel Pharmaceuticals Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CLVLY or ATHE?
Clinuvel Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Clinuvel Pharmaceuticals Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Clinuvel Pharmaceuticals Ltd.'s price-to-earnings ratio is 17.59x while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clinuvel Pharmaceuticals Ltd. is 6.70x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLVLYClinuvel Pharmaceuticals Ltd.6.70x 17.59x -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns CLVLY or IMMP?
Immutep Ltd. has a net margin of -- compared to Clinuvel Pharmaceuticals Ltd.'s net margin of --. Clinuvel Pharmaceuticals Ltd.'s return on equity of 19.45% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLVLYClinuvel Pharmaceuticals Ltd.-- -- $135.6M IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About CLVLY or IMMP?
Clinuvel Pharmaceuticals Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 427.78%. Given that Immutep Ltd. has higher upside potential than Clinuvel Pharmaceuticals Ltd., analysts believe Immutep Ltd. is more attractive than Clinuvel Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CLVLYClinuvel Pharmaceuticals Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is CLVLY or IMMP More Risky?
Clinuvel Pharmaceuticals Ltd. has a beta of 1.130, which suggesting that the stock is 13.043% more volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.925, suggesting its more volatile than the S&P 500 by 92.469%.
-
Which is a Better Dividend Stock CLVLY or IMMP?
Clinuvel Pharmaceuticals Ltd. has a quarterly dividend of $0.03 per share corresponding to a yield of 0.4%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clinuvel Pharmaceuticals Ltd. pays 5.58% of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend. Clinuvel Pharmaceuticals Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CLVLY or IMMP?
Clinuvel Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Clinuvel Pharmaceuticals Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Clinuvel Pharmaceuticals Ltd.'s price-to-earnings ratio is 17.59x while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clinuvel Pharmaceuticals Ltd. is 6.70x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLVLYClinuvel Pharmaceuticals Ltd.6.70x 17.59x -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns CLVLY or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Clinuvel Pharmaceuticals Ltd.'s net margin of --. Clinuvel Pharmaceuticals Ltd.'s return on equity of 19.45% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital CLVLYClinuvel Pharmaceuticals Ltd.-- -- $135.6M KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About CLVLY or KZIA?
Clinuvel Pharmaceuticals Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $16.49 which suggests that it could grow by 9.6%. Given that Kazia Therapeutics Ltd. has higher upside potential than Clinuvel Pharmaceuticals Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Clinuvel Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CLVLYClinuvel Pharmaceuticals Ltd.0 0 0 KZIAKazia Therapeutics Ltd.0 0 0 -
Is CLVLY or KZIA More Risky?
Clinuvel Pharmaceuticals Ltd. has a beta of 1.130, which suggesting that the stock is 13.043% more volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.185%.
-
Which is a Better Dividend Stock CLVLY or KZIA?
Clinuvel Pharmaceuticals Ltd. has a quarterly dividend of $0.03 per share corresponding to a yield of 0.4%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clinuvel Pharmaceuticals Ltd. pays 5.58% of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend. Clinuvel Pharmaceuticals Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CLVLY or KZIA?
Clinuvel Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Clinuvel Pharmaceuticals Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Clinuvel Pharmaceuticals Ltd.'s price-to-earnings ratio is 17.59x while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clinuvel Pharmaceuticals Ltd. is 6.70x versus 680.02x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLVLYClinuvel Pharmaceuticals Ltd.6.70x 17.59x -- -- KZIAKazia Therapeutics Ltd.680.02x -- -- --
-
Which has Higher Returns CLVLY or MESO?
Mesoblast Ltd. has a net margin of -- compared to Clinuvel Pharmaceuticals Ltd.'s net margin of --. Clinuvel Pharmaceuticals Ltd.'s return on equity of 19.45% beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLVLYClinuvel Pharmaceuticals Ltd.-- -- $135.6M MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About CLVLY or MESO?
Clinuvel Pharmaceuticals Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 95.86%. Given that Mesoblast Ltd. has higher upside potential than Clinuvel Pharmaceuticals Ltd., analysts believe Mesoblast Ltd. is more attractive than Clinuvel Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CLVLYClinuvel Pharmaceuticals Ltd.0 0 0 MESOMesoblast Ltd.1 0 0 -
Is CLVLY or MESO More Risky?
Clinuvel Pharmaceuticals Ltd. has a beta of 1.130, which suggesting that the stock is 13.043% more volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.508%.
-
Which is a Better Dividend Stock CLVLY or MESO?
Clinuvel Pharmaceuticals Ltd. has a quarterly dividend of $0.03 per share corresponding to a yield of 0.4%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clinuvel Pharmaceuticals Ltd. pays 5.58% of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend. Clinuvel Pharmaceuticals Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CLVLY or MESO?
Clinuvel Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than Mesoblast Ltd. quarterly revenues of --. Clinuvel Pharmaceuticals Ltd.'s net income of -- is lower than Mesoblast Ltd.'s net income of --. Notably, Clinuvel Pharmaceuticals Ltd.'s price-to-earnings ratio is 17.59x while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clinuvel Pharmaceuticals Ltd. is 6.70x versus 125.41x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLVLYClinuvel Pharmaceuticals Ltd.6.70x 17.59x -- -- MESOMesoblast Ltd.125.41x -- -- --
-
Which has Higher Returns CLVLY or PPCB?
has a net margin of -- compared to Clinuvel Pharmaceuticals Ltd.'s net margin of --. Clinuvel Pharmaceuticals Ltd.'s return on equity of 19.45% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLVLYClinuvel Pharmaceuticals Ltd.-- -- $135.6M PPCB-- -$0.00 -- -
What do Analysts Say About CLVLY or PPCB?
Clinuvel Pharmaceuticals Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Clinuvel Pharmaceuticals Ltd. has higher upside potential than , analysts believe Clinuvel Pharmaceuticals Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings CLVLYClinuvel Pharmaceuticals Ltd.0 0 0 PPCB0 0 0 -
Is CLVLY or PPCB More Risky?
Clinuvel Pharmaceuticals Ltd. has a beta of 1.130, which suggesting that the stock is 13.043% more volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock CLVLY or PPCB?
Clinuvel Pharmaceuticals Ltd. has a quarterly dividend of $0.03 per share corresponding to a yield of 0.4%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clinuvel Pharmaceuticals Ltd. pays 5.58% of its earnings as a dividend. pays out -- of its earnings as a dividend. Clinuvel Pharmaceuticals Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CLVLY or PPCB?
Clinuvel Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Clinuvel Pharmaceuticals Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Clinuvel Pharmaceuticals Ltd.'s price-to-earnings ratio is 17.59x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clinuvel Pharmaceuticals Ltd. is 6.70x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLVLYClinuvel Pharmaceuticals Ltd.6.70x 17.59x -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 67.45% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 10.86% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.22% over the past day.
